| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
5-LOX-IN-2 targets 5-lipoxygenase (5-LOX), a key enzyme in the arachidonic acid cascade that catalyzes the formation of leukotrienes, which are potent inflammatory mediators. 5-LOX is involved in inflammation, allergic responses, and cancer. 5-LOX-IN-2 is a 5-LOX inhibitor with an IC50 of 0.33 μM. It inhibits 5-LOX in a dose-dependent manner.
|
|---|---|
| ln Vitro |
5-LOX-IN-2 (Compound 10b) has a cytotoxic effect on renal cancer cells and is specific to RCC4 and 786.0 cells that lack the Von Hippel-Lindau (VHL) inhibitory oncogene. In RCC4 cells, 5-LOX-IN-2 (Compound 10b) (0-10 μM; 24 hours) can also upregulate p62 and LC3B expression, inhibit autophagy carriers, and promote cell proliferation through activation of the caspase-3 pathway. 1].
In vitro, 5-LOX-IN-2 is a 5-lipoxygenase inhibitor with an IC50 of 0.33 μM. It inhibits 5-LOX in a dose-dependent manner. 5-LOX-IN-2 reduces the cell viability of renal cancer cells and induces apoptosis. These in vitro properties make 5-LOX-IN-2 a valuable tool for studying 5-LOX biology and its role in cancer and inflammatory diseases. |
| ln Vivo |
In vivo, 5-LOX-IN-2 has shown significant anticancer activity by reducing cell viability and inducing apoptosis in renal cancer cells. It may be utilized in cancer-related research. However, detailed in vivo efficacy data are limited in publicly available sources. The compound's activity against 5-LOX suggests potential for treating inflammatory diseases and cancer.
|
| Enzyme Assay |
The in vitro enzyme assay for 5-LOX-IN-2 involves measuring its inhibition of 5-lipoxygenase enzymatic activity. Recombinant 5-LOX is incubated with the compound at various concentrations in the presence of arachidonic acid substrate. 5-LOX activity is measured by quantifying the production of leukotrienes or other 5-LOX products using HPLC, LC-MS/MS, or spectrophotometric methods. The IC50 for 5-LOX inhibition is calculated from dose-response curves.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: RCC4, RCC10, 786.0 Cell Tested Concentrations: 0-100 μM Incubation Duration: 4 days Experimental Results: The cell viability of renal cancer cells is diminished and the selectivity is stronger. RCC4 and 786.0 cells lack the Von Hippel-Lindau (VHL) tumor suppressor gene. Western Blot Analysis[1] Cell Types: RCC4, RCC10, 786.0 Cell Tested Concentrations: 0-10 μM Incubation Duration: 24 hrs (hours) Experimental Results: LC3B and p62 expression increased and autophagy flow was blocked in RCC4 cells. Cleavage of caspase-3 precursors was stimulated in a dose-dependent manner only in RCC4 cells lacking the VHL tumor suppressor. The in vitro cell-based assay for 5-LOX-IN-2 involves culturing renal cancer cells or other cell lines and treating them with the compound to assess effects on cell viability and apoptosis. Cells are treated with 5-LOX-IN-2 at various concentrations for 24-72 hours. Cell viability is assessed using MTT, CellTiter-Glo, or SRB assays. Apoptosis is assessed by measuring caspase activity, Annexin V/PI staining, or DNA fragmentation. 5-LOX activity in cells can be measured by quantifying leukotriene production by ELISA. |
| Animal Protocol |
In vivo animal studies for 5-LOX-IN-2 have not been extensively reported. If conducted, such studies might involve mouse xenograft models of renal cancer or models of inflammatory diseases. 5-LOX-IN-2 would be administered orally or intraperitoneally, and tumor growth, inflammatory markers, or disease severity would be assessed. Standard protocols for cancer or inflammation models would be employed. No specific data are available.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 5-LOX-IN-2 have not been extensively characterized. As a small molecule with a molecular weight of 284.31 and a molecular formula of C17H16O4, it is expected to have moderate oral bioavailability. The compound can be formulated for in vivo administration. Detailed PK parameters such as half-life, Cmax, and bioavailability are not available from publicly accessible sources.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 5-LOX-IN-2 has not been systematically evaluated. As a 5-LOX inhibitor, its primary safety concerns would relate to effects on leukotriene production and immune function. Standard toxicology assessments would include acute and sub-chronic toxicity studies in rodents, with endpoints including clinical signs, body weight, clinical pathology, and histopathology. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
5-LOX-IN-2 is a research compound and has not been approved for clinical use. It is a 5-lipoxygenase inhibitor with an IC50 of 0.33 μM. 5-LOX-IN-2 inhibits 5-LOX in a dose-dependent manner and reduces the cell viability of renal cancer cells and induces apoptosis. It can be used for cancer research and is a valuable tool for studying 5-LOX biology in inflammation and cancer.
|
| Molecular Formula |
C17H16O4
|
|---|---|
| Molecular Weight |
284.31
|
| Exact Mass |
284.104
|
| Elemental Analysis |
C, 71.82; H, 5.67; O, 22.51
|
| CAS # |
179691-97-5
|
| PubChem CID |
5909099
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
515.5±50.0 °C at 760 mmHg
|
| Flash Point |
192.2±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.646
|
| LogP |
3.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
347
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CCOC(=O)/C=C/C2=C(C=CC(=C2)O)O
|
| InChi Key |
OQKRMXDGEFRBAJ-RMKNXTFCSA-N
|
| InChi Code |
InChI=1S/C17H16O4/c18-15-7-8-16(19)14(12-15)6-9-17(20)21-11-10-13-4-2-1-3-5-13/h1-9,12,18-19H,10-11H2/b9-6+
|
| Chemical Name |
phenethyl (E)-3-(2,5-dihydroxyphenyl)acrylate
|
| Synonyms |
NSC666588; CHEMBL131678; NSC-666588; 5LOX-IN-2; 5-LOX-IN2; 5-LOX-IN-2
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~351.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5173 mL | 17.5864 mL | 35.1729 mL | |
| 5 mM | 0.7035 mL | 3.5173 mL | 7.0346 mL | |
| 10 mM | 0.3517 mL | 1.7586 mL | 3.5173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
